AnGes ^Investors

AnGes MG, Inc. is a biopharmaceutical company that focuses on the development of innovative gene medicine. Founded in 1999, AnGes aims to provide effective therapies for patients suffering from diseases that currently have no available treatment options. They have already successfully marketed "Naglazyme®," a drug for the treatment of mucopolysaccharidosis VI, and are in the final stages of clinical development for HGF Plasmid, a gene therapy for critical limb ischemia. Additionally, AnGes is working on the development of a nucleic acid medicine to suppress various types of inflammation and a medical device for the prevention of vascular restenosis. With a commitment to practical application and global leadership in gene medicine, AnGes strives to meet the expectations of patients, families, shareholders, investors, and the general public.